Published in Surgery on December 01, 2010
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol (2014) 4.75
Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol (2011) 2.96
Progress in molecular-based management of differentiated thyroid cancer. Lancet (2013) 2.44
BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab (2012) 1.39
The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One (2012) 1.34
Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. J Clin Endocrinol Metab (2015) 1.24
Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab (2012) 1.24
German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg (2013) 1.23
BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients? World J Surg (2014) 1.00
Suspicious ultrasound characteristics predict BRAF V600E-positive papillary thyroid carcinoma. Thyroid (2012) 0.94
Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery (2012) 0.94
Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype. J Clin Endocrinol Metab (2013) 0.90
BRAF mutation in papillary thyroid carcinoma. Int J Clin Exp Med (2012) 0.88
Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. World J Surg Oncol (2016) 0.86
RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma. J Clin Endocrinol Metab (2013) 0.86
BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid (2014) 0.85
Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma. Oncol Lett (2013) 0.84
The association between BRAF (V600E) mutation and pathological features in PTC. Eur Arch Otorhinolaryngol (2014) 0.84
A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. Am J Surg Pathol (2015) 0.83
Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma. Eur J Endocrinol (2012) 0.81
Selective use of sorafenib in the treatment of thyroid cancer. Drug Des Devel Ther (2016) 0.79
Identification of Intermediate- to High-Risk Papillary Thyroid Carcinoma Patients Who May Be Safely Managed without the Performance of Delayed Stimulated Thyroglobulin Measurements following Total Thyroidectomy and Radioactive Iodine Therapy. Int J Endocrinol (2015) 0.75
Intensive versus conventional glucose control in critically ill patients. N Engl J Med (2009) 26.30
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
Hypoglycemia and risk of death in critically ill patients. N Engl J Med (2012) 6.17
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab (2005) 4.07
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet (2005) 2.85
Worldwide trends in the surgical treatment of primary hyperparathyroidism in the era of minimally invasive parathyroidectomy. Arch Surg (2002) 2.38
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol (2013) 2.26
A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery (2011) 2.11
Pheochromocytoma: current approaches and future directions. Oncologist (2008) 2.05
A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res (2005) 1.95
Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol (2009) 1.94
qpure: A tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PLoS One (2012) 1.77
Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am J Surg Pathol (2010) 1.73
Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. Pathology (2010) 1.65
Bone as a source of FGF23: regulation by phosphate? Bone (2004) 1.63
miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer. Clin Cancer Res (2009) 1.62
Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. J Clin Endocrinol Metab (2013) 1.61
Potential pitfalls in the diagnosis of phaeochromocytoma. Med J Aust (2005) 1.61
Clinical and immunohistochemical features of 34 solid pseudopapillary tumors of the pancreas. J Gastroenterol Hepatol (2011) 1.60
Surgeon performed ultrasound facilitates minimally invasive parathyroidectomy by the focused lateral mini-incision approach. World J Surg (2008) 1.59
Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol (2010) 1.56
Minimally invasive thyroid surgery for single nodules: an evidence-based review of the lateral mini-incision technique. World J Surg (2008) 1.53
Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res (2009) 1.53
Expanding indications for recombinant human TSH in thyroid cancer. Thyroid (2008) 1.49
Association of the TSHR gene with Graves' disease: the first disease specific locus. Eur J Hum Genet (2005) 1.49
Use of the Nerve Integrity Monitor during Thyroid Surgery Aids Identification of the External Branch of the Superior Laryngeal Nerve. Ann Surg Oncol (2014) 1.46
Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomas. Clin Endocrinol (Oxf) (2013) 1.46
Academic health science centres in Australia: let's get competitive. Med J Aust (2011) 1.43
Thyroid neoplasia following irradiation in adolescent and young adult survivors of childhood cancer. Med J Aust (2002) 1.43
Minimal access thyroid surgery: is it feasible, is it appropriate? ANZ J Surg (2002) 1.41
Post-operative partial hypoparathyroidism: an under-recognized disorder. ANZ J Surg (2012) 1.39
Completion thyroidectomy for malignancy after initial minimal access thyroid surgery. ANZ J Surg (2006) 1.37
Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol (2010) 1.32
Horner's syndrome in association with thyroid and parathyroid disease. ANZ J Surg (2004) 1.30
The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell (2013) 1.30
Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol (2007) 1.29
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res (2006) 1.27
Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int J Cancer (2014) 1.24
Parathyroid hormone assay predicts hypocalcaemia after total thyroidectomy. ANZ J Surg (2007) 1.24
Clinical case seminar: Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab (2003) 1.22
MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin Cancer Res (2011) 1.22
Renal tumors associated with germline SDHB mutation show distinctive morphology. Am J Surg Pathol (2011) 1.21
Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol (2011) 1.19
Phaeochromocytoma: current concepts. Med J Aust (2005) 1.18
BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol (2013) 1.16
Intrapancreatic splenunculus. Am J Surg (2007) 1.16
Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) (2008) 1.15
Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4. N Engl J Med (2011) 1.14
Minimal-access/minimally invasive parathyroidectomy for primary hyperparathyroidism. Surg Clin North Am (2004) 1.14
Total thyroidectomy is now the preferred option for the surgical management of Graves' disease. ANZ J Surg (2002) 1.13
Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab (2002) 1.12
1000 minimally invasive parathyroidectomies without intra-operative parathyroid hormone measurement: lessons learned. ANZ J Surg (2010) 1.11
MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer (2010) 1.11
Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol (2014) 1.11
Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist (2008) 1.09
External ophthalmic findings in multiple endocrine neoplasia type 2B. Clin Experiment Ophthalmol (2004) 1.09
Elevated serum FGF23 concentrations in plasma cell dyscrasias. Bone (2006) 1.09